End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma

Lale Kostakoglu, Grzegorz S. Nowakowski

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


“PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS.”

Original languageEnglish (US)
Pages (from-to)307-315
Number of pages9
JournalPET Clinics
Issue number3
StatePublished - Jul 2019


  • Diffuse large B-cell lymphoma
  • End-of-treatment PET-CT
  • Prediction of outcome

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma'. Together they form a unique fingerprint.

Cite this